Maurício Morais
Instituto Superior Técnico
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Maurício Morais.
Molecular Pharmaceutics | 2011
Maurício Morais; Suresh Subramanian; Usha Pandey; Grace Samuel; Meera Venkatesh; Manuel A. Martins; S. Pereira; João D. G. Correia; Isabel Santos
Despite being widely used in the clinical setting for sentinel lymph node detection (SLND), (99m)Tc-based colloids (e.g., (99m)Tc-human serum albumin colloids) present a set of properties that are far from ideal. Aiming to design novel compounds with improved biological properties, we describe herein the first class of fully characterized (99m)Tc(CO)₃-mannosylated dextran derivatives with adequate features for SLND. Dextran derivatives, containing the same number of pendant mannose units (13) and a variable number (n) of tridentate chelators (9, n = 1; 10, n = 4, 11, n= 12), have been synthesized and fully characterized. Radiolabeled polymers of the type fac-[(99m)Tc(CO)₃(k³-L)] (12, L = 9, 13, L = 10, 14, L = 11) have been obtained quantitatively in high radiochemical purity (≥ 98%) upon reaction of the dextran derivatives with fac-[(99m)Tc(CO)₃(H₂O)₃]+. The highly stable compounds 13 and 14 were identified by comparing their HPLC chromatograms with the ones obtained for the corresponding rhenium surrogates fac-[Re(CO)₃(k³-10)] (13a) and fac-[Re(CO)₃(k³-11)] (14a), which have been characterized both at the chemical (NMR and IR spectroscopy, and HPLC) and physical level (DLS, AFM and LDV). Compounds 13a and 14a present a positive zeta potential (+ 7.1 mV, pH 7.4) and a hydrodynamic diameter in the range 8.4-8.7 nm. Scintigraphic imaging and biodistribution studies in Wistar rats have shown good accumulation in the sentinel node at 60 min postinjection (6.71 ± 2.35%, 13; and 7.53 ± 0.69%, 14), with significant retention up to 180 min. A clear delineation of the sentinel lymph node without significant washout to other regions was observed in the scintigraphic images. The popliteal extraction of 94.47 ± 2.45% for 14 at 1 h postinjection, as compared to 61.81 ± 2.4% for 13, indicated that 14 is a very promising compound to be further explored as SLN imaging agent.
Journal of Medicinal Chemistry | 2013
Maurício Morais; Bruno L. Oliveira; J. G. Correia; Maria Cristina Oliveira; Maria Angeles Jiménez; Isabel Santos; Paula D. Raposinho
Aiming at the design of specific melanocortin-1 receptor (MC1R) targeted imaging probes, we report on the effect of different azolyl-ring substitution patterns (carboxylate at the 4-position and/or methyl groups at the 3,5 positions) of pyrazolyl-diamine bifunctional chelators (Pz(2)-Pz(4)) on the pharmacokinetic profile of the (99m)Tc(CO)3-labeled lactam bridge-cyclized α-melanocyte stimulating hormone derivative, βAlaNleCycMSH(hex). Three pyrazolyl-diamine-containing chelators were conjugated to βAlaNleCycMSHhex, with the resulting peptide conjugates displaying subnanomolar MC1R binding affinity. Biodistribution studies in B16F1 melanoma-bearing mice show that all radiopeptides present a good melanoma uptake. The introduction of a carboxylate group in the azolyl-ring leads to a remarkable reduction of the kidney (>89%) and liver (>91%) accumulation for (99m)Tc(CO)3-Pz(3)-βAlaNleCycMSH(hex) and (99m)Tc(CO)3-Pz(4)-βAlaNleCycMSH(hex) when compared to the radiopeptide (99m)Tc(CO)3-Pz(1)-βAlaNleCycMSH(hex), where that group is absent. The good tumor uptake and favorable tumor-to-nontarget-organs ratios of (99m)Tc(CO)3-Pz(3)-βAlaNleCycMSH(hex) and (99m)Tc(CO)3-Pz(4)-βAlaNleCycMSH(hex) highlights the potential of both compounds as melanoma imaging agents.
Bioconjugate Chemistry | 2014
Maurício Morais; Maria Paula Cabral Campello; Catarina Xavier; Johannes Heemskerk; D. G. Correia; Tony Lahoutte; Vicky Caveliers; Sophie Hernot; Isabel Santos
Current methods for sentinel lymph node (SLN) mapping involve the use of radioactivity detection with technetium-99m sulfur colloid and/or visually guided identification using a blue dye. To overcome the kinetic variations of two individual imaging agents through the lymphatic system, we report herein on two multifunctional macromolecules, 5a and 6a, that contain a radionuclide ((99m)Tc or (68)Ga) and a near-infrared (NIR) reporter for pre- and/or intraoperative SLN mapping by nuclear and NIR optical imaging techniques. Both bimodal probes are dextran-based polymers (10 kDa) functionalized with pyrazole-diamine (Pz) or 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelating units for labeling with fac-[(99m)Tc(CO)3](+) or (68)Ga(III), respectively, mannose units for receptor targeting, and NIR fluorophore units for optical imaging. The probes allowed a clear visualization of the popliteal node by single-photon emission computed tomography (SPECT/CT) or positron emission tomography (PET/CT), as well as real-time optically guided excision. Biodistribution studies confirmed that both macromolecules present a significant accumulation in the popliteal node (5a: 3.87 ± 0.63% IA/organ; 6a: 1.04 ± 0.26% IA/organ), with minimal spread to other organs. The multifunctional nanoplatforms display a popliteal extraction efficiency >90%, highlighting their potential to be further explored as dual imaging agents.
Nuclear Medicine and Biology | 2014
Maurício Morais; Cátia Cantante; Lurdes Gano; Isabel Santos; Sara Lourenço; Catarina Santos; Carlos M. G. A. Fontes; Frederico Aires da Silva; João Gonçalves; João D. G. Correia
INTRODUCTION Small domain antibodies (sdAbs) present high potential for both molecular in vivo imaging and therapy. Owing to the low molecular weight they are rapidly cleared from blood circulation, and new strategies to extend their half-lifes are needed for therapeutic applications. We have selected a bacterial albumin-binding domain (ABD) from protein Zag to be fused to an anti-tumor necrosis factor (TNF) single variable-domain heavy-chain region antibody (VHH) to delay blood clearance, and evaluated the biodistribution profile of the fusion protein. METHODS The anti-TNF VHH and the fusion protein VHH-Zag were conjugated to S-2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (p-SCN-Bn-NOTA). The anti-TNF and albumin-binding properties of the conjugates NOTA-VHH and NOTA-VHH-Zag were assessed by enzyme-linked immunosorbent assay (ELISA). The radioconjugates (67)Ga-NOTA-VHH and (67)Ga-NOTA-VHH-Zag were obtained by reaction of (67)GaCl3 with the corresponding conjugates at room temperature. Biodistribution studies were performed in healthy female CD-1 mice. RESULTS The immunoreactivity of the VHH-based proteins is preserved upon conjugation to NOTA as well as after radiometallation. The radiochemical purity of the radioconjugates was higher than 95% as determined by ITLC-SG after purification by gel filtration. The biodistribution studies showed that the Zag domain affected the pharmacokinetic properties of VHH, with impressive differences in blood clearance (0.028 ± 0.004 vs 1.7 ± 0.8 % I.A./g) and total excretion (97.8 ± 0.6 vs 25.5 ± 2.1 % I.A.) for (67)Ga-NOTA-VHH and (67)Ga-NOTA-VHH-Zag, respectively, at 24h p.i. CONCLUSION The Zag domain prolonged the circulation time of VHH by reducing the blood clearance of the labeled fusion protein (67)Ga-NOTA-VHH-Zag. In this way, the anti-TNF VHH in fusion with the Zag ABD presents a higher therapeutic potential than the unmodified VHH.
Chemical Biology & Drug Design | 2015
Bruno L. Oliveira; Maurício Morais; Filipa Mendes; Irina S. Moreira; Carlos Cordeiro; Pedro A. Fernandes; Maria J. Ramos; Roger Alberto; Isabel Santos; João D. G. Correia
Aiming to design 99mTc complexes for probing nitric oxide synthase (NOS) by SPECT, we synthesized conjugates (L4–L6) comprising a NOS‐recognizing moiety connected to a diamino‐propionic acid (dap) chelating unit. The conjugates led to complexes of the type fac‐[M(CO)3(ĸ3‐L)] (M = Re/99mTc; Re4/Tc4: L = L4; Re5/Tc5: L = L5; Re6/Tc6: L = L6). Enzymatic studies showed that L4 and L5, but not L6, gave complexes (Re4 and Re5) that are less potent than the conjugates. To rationalize these results, we performed docking and molecular dynamics simulations. The high affinity of L4 and L5 is due to the strong interactions between the dap chelator and polar residues of the binding cavity. These interactions are hampered by metallation resulting in complexes with lower affinity. The higher potency of Re5 compared to Re4 was assigned to the increased bulkiness of Re5 and the presence of additional anchoring groups that better fit the active site and provide more extensive contacts. In turn, Re6 is too bulky and its organometallic tail is oriented toward the peripheral pocket of iNOS, leading to loss of contacts and a lower affinity. These results were compared with our previous results obtained with analogue complexes stabilized by a pyrazolyl‐diamine chelating unit.
Journal of Biotechnology | 2017
Cátia Cantante; Sara Lourenço; Maurício Morais; João Leandro; Lurdes Gano; Nuno Silva; Paula Leandro; Mónica Serrano; Adriano O. Henriques; Ana S. André; Catarina Cunha-Santos; Carlos M. G. A. Fontes; João D. G. Correia; Frederico Aires-da-Silva; João Gonçalves
Recombinant antibody fragments belong to the promising class of biopharmaceuticals with high potential for future therapeutic applications. However, due to their small size they are rapidly cleared from circulation. Binding to serum proteins can be an effective approach to improve pharmacokinetic properties of short half-life molecules. Herein, we have investigated the Zag albumin-binding domain (ABD) derived from Streptococcus zooepidemicus as a novel strategy to improve the pharmacokinetic properties of therapeutic molecules. To validate our approach, the Zag ABD was fused with an anti-TNFα single-domain antibody (sdAb). Our results demonstrated that the sdAb-Zag fusion protein was highly expressed and specifically recognizes human, rat and mouse serum albumins with affinities in the nanomolar range. Moreover, data also demonstrated that the sdAb activity against the therapeutic target (TNFα) was not affected when fused with Zag ABD. Importantly, the Zag ABD increased the sdAb half-life ∼39-fold (47min for sdAb versus 31h for sdAb-Zag). These findings demonstrate that the Zag ABD fusion is a promising approach to increase the half-life of small recombinant antibodies molecules without affecting their therapeutic efficacy. Moreover, the present study strongly suggests that the Zag ABD fusion strategy can be potentially used as a universal method to improve the pharmokinetics properties of many others therapeutics proteins and peptides in order to improve their dosing schedule and clinical effects.
ACS Chemical Biology | 2017
Vera Neves; Frederico Aires-da-Silva; Maurício Morais; Lurdes Gano; Elisabete Ribeiro; Antónia R. T. Pinto; Sandra Aguiar; Diana Gaspar; Célia Fernandes; João D. G. Correia; Miguel A. R. B. Castanho
The delivery of therapeutic molecules to the central nervous system is hampered by poor delivery across the blood-brain barrier (BBB). Several strategies have been proposed to enhance transport into the brain, including invasive techniques and receptor-mediated transport (RMT). Both approaches have several drawbacks, such as BBB disruption, receptor saturation, and off-target effects, raising safety issues. Herein, we show that specific domains of Dengue virus type 2 capsid protein (DEN2C) can be used as trans-BBB peptide vectors. Their mechanism of translocation is receptor-independent and consistent with adsorptive-mediated transport (AMT). One peptide in particular, named PepH3, reaches equilibrium distribution concentrations across the BBB in less than 24 h in a cellular in vitro assay. Importantly, in vivo biodistribution data with radiolabeled peptide derivatives show high brain penetration. In addition, there is fast clearance from the brain and high levels of excretion, showing that PepH3 is a very good candidate to be used as a peptide shuttle taking cargo in and out of the brain.
Molecules | 2017
Maurício Morais; Héctor Zamora-Carreras; Paula D. Raposinho; Maria Cristina Oliveira; David Pantoja-Uceda; João D. G. Correia; Maria Angeles Jiménez
Linear and cyclic analogues of the α-melanocyte stimulating hormone (α-MSH) targeting the human melanocortin receptor 1 (MC1R) are of pharmacological interest for detecting and treating melanoma. The central sequence of α-MSH (His-Phe-Arg-Trp) has been identified as being essential for receptor binding. To deepen current knowledge on the molecular basis for α-MSH bioactivity, we aimed to understand the effect of cycle size on receptor binding. To that end, we synthesised two macrocyclic isomeric α-MSH analogues, c[NH-NO2-C6H3-CO-His-DPhe-Arg-Trp-Lys]-Lys-NH2 (CycN-K6) and c[NH-NO2-C6H3-CO-His-DPhe-Arg-Trp-Lys-Lys]-NH2 (CycN-K7). Their affinities to MC1R receptor were determined by competitive binding assays, and their structures were analysed by 1H and 13C NMR. These results were compared to those of the previously reported analogue c[S-NO2-C6H3-CO-His-DPhe-Arg-Trp-Cys]-Lys-NH2 (CycS-C6). The MC1R binding affinity of the 22-membered macrocyclic peptide CycN-K6 (IC50 = 155 ± 16 nM) is higher than that found for the 25-membered macrocyclic analogue CycN-K7 (IC50 = 495 ± 101 nM), which, in turn, is higher than that observed for the 19-membered cyclic analogue CycS-C6 (IC50 = 1770 ± 480 nM). NMR structural study indicated that macrocycle size leads to changes in the relative dispositions of the side chains, particularly in the packing of the Arg side chain relative to the aromatic rings. In contrast to the other analogues, the 22-membered cycle’s side chains are favorably positioned for receptor interaction.
Archive | 2014
Maurício Morais; Paula D. Raposinho; Maria Cristina Oliveira; Isabel Santos; David Pantoja-Uceda; M. Angeles Jiménez; J. G. Correia
Keywords: azobenzene ; photoswitchable peptide ; light-responsive ligand ; optogenetics ; phage display ; streptavidin Reference EPFL-CONF-202371doi:10.1002/psc.2688View record in Web of Science Record created on 2014-10-23, modified on 2017-05-12Cyclic lipodepsipeptides (CLPs) are a diverse group of secondary metabolites produced by various bacteria with important biological functions, but with yet unresolved molecular mechanisms. Our previous efforts have gone towards characterizing with NMR the conformation and self-assembling properties of a collection of CLPs known as the viscosin group. [1-4] CLPs increasingly attract attention because of their antifungal and antibiotic properties through membrane permeabilization. A full understanding of their membrane interactions is essential to elucidate the exact working mechanism of CLPs. To obtain comprehensive structural information in a membrane environment, we have used liquid-state NMR and model membrane systems, such as micelles and isotropic lipid bicelles. Like micelles, isotropic bicelles display favourable NMR relaxation properties, while possessing structural characteristics of lipid bilayers. [5] The orientation and insertion depth of CLPs in a membrane environment can be investigated using diffusion NMR and paramagnetic relaxation enhancement measurements. The latter is achieved by introducing paramagnetic probes at various locations. By introducing a water-soluble paramagnetic complex to a bicelle sample, NMR signals from nuclei closer to the aqueous phase can be identified. Adding lipid molecules with covalently linked paramagnetic radicals at various positions deliver the orientation and the insertion depth of the peptides in the bilayer. Finally, 31P longitudinal relaxation measurements allow to obtain detailed information regarding the local dynamics of the lipid head groups of the bicelles. [6] The NMR results are complemented with other experimental techniques, including fluorescence spectroscopy, circular dichroism and infrared spectroscopy. We have also performed all-atom molecular dynamics (MD) simulations of CLPs within lipid membranes, which can be confronted with the experimental NMR results. References 1. Sinnaeve, D., Hendrickx, P.M. et al., Chemistry - A European Journal, 2009, 15(46): 12653-12662 2. Sinnaeve, D., Delsuc, M.-A. et al., Chemical Science, 2012, 3: 1284-1292 3. De Vleeschouwer, M., Sinnaeve D. et al., Chemistry - A European Journal, 2014, 20(25): 7766-7775 4. Geudens N., De Vleeschouwer M. et al., ChemBioChem, 2014, 15: 2736-2746 5. Durr, U. H., Gildenberg M. et al., Chem Rev, 2014, 112(11): 6054-6074 6. Bodor, A., Kover, E et al., BBA Biomembranes, 2015, 1848(3): 760-766No abstract is available for this article.
Journal of Organometallic Chemistry | 2013
Maurício Morais; António Paulo; Lurdes Gano; Isabel Santos; João D. G. Correia